The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | CD20 targeted CAR-T: MB-106 in B-NHL and CLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of the use of MB-106, a 3rd generation CD20-targeted chimeric antigen receptor (CAR) T-cell therapy, for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). A Phase I/II trial (NCT03277729) investigating the safety and efficacy of MB-106 for high-risk B-NHL and CLL has reported a complete response rate of 82% amongst 11 patients with follicular lymphoma. No grade three or four cytokine release syndrome has been reported in patients with follicular lymphoma. A patient with high-risk CLL had a complete response to MB-106 with no detectable measurable residual disease (MRD). Dr Shadman comments on these findings, highlighting MB-106’s promising safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
